The new 7,000-square-meter plant is located in France and will begin production of thorium-228, necessary for the development of isotopes used in cancer treatments.
The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
The popular DOAC was linked to more bleeding events than warfarin, but fewer reports of intracardiac thrombi and other adverse outcomes. Researchers presented their findings at the AHA's Scientific Sessions 2024 conference in Chicago.
In this RB opinion piece, Radiology Business Management Association leaders discuss what President-elect Trump's 2nd term might mean for the specialty.
![Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S](/sites/default/files/styles/top_stories/public/2024-08/screenshot_2024-08-12_at_11.35.13_am.png.webp?itok=5FeQeMFj)
